Completed
Oral Ganciclovir Maintenance for CMV Retinitis in Patients With Limited Venous Access
What is being tested
Ganciclovir
Drug
Who is being recruted
Blood-Borne Infections+30
+ Urogenital Diseases
+ Genital Diseases
Over 13 Years
+10 Eligibility Criteria
How is the trial designed
Treatment Study
Interventional
Summary
Principal SponsorHoffmann-La Roche
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Patients receive oral ganciclovir as maintenance. Patients enrolled at time of closure of enrollment will receive 2 months of study drug and undergo follow-up.
Principal SponsorHoffmann-La Roche
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 13 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesAmino Acid Metabolism, Inborn ErrorsCommunicable DiseasesCytomegalovirus InfectionsDNA Virus InfectionsEye DiseasesHerpesviridae InfectionsImmunologic Deficiency SyndromesImmune System DiseasesInfectionsMetabolic DiseasesMetabolism, Inborn ErrorsCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesNutritional and Metabolic DiseasesRetinal DiseasesRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSlow Virus DiseasesVirus DiseasesSexually Transmitted Diseases, ViralEye InfectionsEye Infections, ViralLentivirus InfectionsMitochondrial DiseasesGenetic Diseases, InbornAcquired Immunodeficiency SyndromeRetinitisHIV InfectionsCytomegalovirus RetinitisMultiple Acyl Coenzyme A Dehydrogenase Deficiency
Criteria
6 inclusion criteria required to participate
AIDS
Consent of guardian if less than legal age of consent
Had a permanent central IV catheter removed two or more times within the past 6 months due to catheter infection or thrombosis
No permanent central IV catheter at present
Show More Criteria
4 exclusion criteria prevent from participating
Any other concomitant medications precluded by the protocol
History of hypersensitivity to acyclovir or ganciclovir
Intravitreal anti-CMV treatment
Require continuation of concomitant medications precluded by this protocol
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Roche Global Development - Palo Alto
Palo Alto, United StatesOpen Roche Global Development - Palo Alto in Google MapsCompletedOne Study Center